Bioportides: Bioactive cell-penetrating peptides that modulate cellular dynamics

Biotechnology Journal

Volumn 8, Issue 8, 2013, Pages 918-930

  Lukanowska, Monika ^a   Howl, John ^a   Jones, Sarah ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Cell signalling; Drug delivery; Therapeutics

Indexed keywords

ANGIOGENESIS; BIOACTIVE PEPTIDES; CANCER; CELL SIGNALLING; CELL-PENETRATING PEPTIDE; CELLULAR INTERNALIZATION; INTRACELLULAR DELIVERY; THERAPEUTICS;

BIOACTIVITY; BIOMIMETICS; CELLS; CYTOLOGY; DRUG DELIVERY; OLIGONUCLEOTIDES;

PEPTIDES;

BIOPORTIDE; CELL PENETRATING PEPTIDE; PENETRATIN; PROTEOME; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; DRUG DEVELOPMENT; HUMAN; INTERNALIZATION; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS; CANCER; CELL SIGNALLING; DRUG DELIVERY; THERAPEUTICS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PHYSIOLOGICAL PROCESSES; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 84881317022     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201200335     Document Type: Review

References (128)

1. Steinhardt, R. A., Bi, G., Alderton, J. M., Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science 1994, 263, 390-393.
2. Lorents, A., Kodavali, P.K., Oskolkov, N., Langel, Ü. et al., Cell-penetrating peptides split into two groups based on modulation of intracellular calcium concentration. J. Biol. Chem. 2012, 287, 16880-16889.
3. Allen, T.M., Cullis, P. R., Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818-1822.
4. Lindgren, M., Hällbrink, M., Prochiantz, A., Langel, Ü., Cell-penetrating peptides. Trends Pharmacol. Sci. 2000, 21, 99-103.
5. Verdurmen, W.P.R., Brock, R., Biological responses towards cationic peptides and drug carriers. Trends Pharmacol. Sci. 2010, 32, 116-124.
6. Mae, M., Langel, Ü., Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 2006, 6, 509-514.
7. Derossi, D., Joliot, A.H., Chassaing, G., Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 269, 10444-10450.
8. Vivès, E., Brodin, P., Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997, 272, 16010-16017.
9. Silhol, M., Tyagi, M., Giacca, M., Lebleu, B. et al., Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 2002, 269, 494-501.
10. Hällbrink, M., Florén, A., Elmquist, A., Pooga, M. et al., Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001, 1515, 101-109.
11. Richard, J.P., Melikov, K., Vives, E., Ramos, C. et al., Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003, 278, 585-590.
12. Tréhin, R., Merkle, H.P., Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur. J. Pharm. Biopharm. 2004, 58, 209-223.
13. Milletti, F., Cell-penetrating peptides: Classes, origin, and current landscape. Drug Discov. Today 2012, 17, 850-860.
14. Jones, S., Martel, C., Belzacq-Casagrande, A.S., Brenner, C. et al., Mitoparan and target-selective chimeric analogues: Membrane translocation and intracellular redistribution induces mitochondrial apoptosis. Biochim. Biophys. Acta 2008, 1783, 849-863.
15. Johansson, H.J., El-Andaloussi, S., Holm, T., Mäe, M. et al., Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol. Ther. 2008, 16, 115-123.
16. Jones, S., Howl, J., Enantiomer-specific bioactivities of peptidomimetic analogues of mastoparan and mitoparan: Characterization of inverso mastoparan as a highly efficient cell penetrating peptide. Bioconjug. Chem. 2012, 23, 47-56.
17. Jones, S., Holm, T., Mäger, I., Langel, Ü. et al., Characterization of bioactive cell penetrating peptides from human cytochrome c: Protein mimicry and the development of a novel apoptogenic agent. Chem.Biol. 2010, 17, 735-744.
18. Delaroche, D., Cantrelle, F.X., Subra, F., Van Heijenoort, C. et al., Cell-penetrating peptides with intracellular actin-remodeling activity in malignant fibroblasts. J. Biol. Chem. 2010, 285, 7712-7721.
19. Howl, J., Jones, S., Proteomimetic cell penetrating peptides. Int. J. Pept. Res. Ther. 2008, 14, 359-366.
20. Bayliss, W.M., Starling, E.H., The mechanism of pancreatic secretion. J. Physiol. 1902, 28, 325-353.
21. Howl, J., Jones, S. (Ed.), Bioactive Peptides. CRC Press, Boca Raton, FL, 2009.
22. Howl, J., Matou-Nasri, S., West, D.C., Farquhar, M. et al., Bioportide: An emergent concept of bioactive cell-penetrating peptides. Cell. Mol. Life. Sci. 2012, 69, 2951-2966.
23. Järver, P., Mäger, I., Langel, Ü., In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci. 2010, 31, 528-535.
24. Jones, A.T., Gateways and tools for drug delivery: Endocytic pathways and the cellular dynamics of cell penetrating peptides. Int. J. Pharm. 2008, 354, 34-38.
25. Hopkins, A.L., Groom, C.R., The druggable genome. Nat. Rev. Drug. Discov. 2002, 1, 727-730.
26. Portoghese, P., Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 198910, 230-235.
27. Hällbrink, M., Kilk, K., Elmquist, A., Lundberg, P. et al., Prediction of cell-penetrating peptides. Int. J. Pept. Res. Ther. 2005, 11, 249-259.
28. Hansen, M., Kilk, K., Langel, Ü., Predicting cell-penetrating peptides. Adv. Drug. Deliv. Rev. 2008, 60, 572-579.
29. Thiel, P., Kaiser, M., Ottmann, C., Small-molecule stabilization of protein-protein interactions: An underestimated concept in drug discovery? Angew. Chem. Int. Ed. Engl. 2012, 51, 2012-2018.
30. Reiss, T., Drug discovery of the future: The implications of the human genome project. Trends Biotechnol. 2001, 19, 496-499.
31. Russ, A.P., Lampel, S., The druggable genome: An update. Drug. Discov. Today 2005, 10, 1607-1610.
32. Rask-Andersen, M., Almén, M.S., Schiöth, H.B., Trends in the exploitation of novel drug targets. Nat. Rev. Drug. Discov. 2011, 10, 579-590.
33. Chen, ZG., Small-molecule delivery by nanoparticles for anticancer therapy. Trends. Mol. Med. 2010, 16, 594-602.
34. Leader, B., Baca, Q.J., Golan, D.E., Protein therapeutics: A summary and pharmacological classification. Nat. Rev. Drug. Discov. 2008, 7, 21-39.
35. Fletcher, S., Hamilton, A.D., Protein surface recognition and proteomimetics: Mimics of protein surface structure and function. Curr. Opin. Chem. Biol. 2005, 9, 632-638.
36. Gante, J., Peptidomimetics - tailored enzyme inhibitors. Angew. Chem. Int. Ed. 1994, 17, 1699-1720.
37. McGregor, D.P., Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 2008, 8, 616-619.
38. Spitz, A., Young, J. M., Larsen, L., Mattia-Goldberg, C. et al., Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012, 15, 93-99.
39. Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T. et al., Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: A 24-week, randomized, multicentre, open-label trial. Hum. Reprod. 2010, 25, 633-641.
40. Heitz, F., Morris, M.C., Divita, G., Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157, 195-206.
41. Temsamani, J., Vidal, P., The use of cell-penetrating peptides for drug delivery. Drug. Discov. Today 2004, 9, 1012-1019.
42. Franke, A.D., Pabo, C.O., Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988, 55, 1189-1193.
43. Truant, R., Cullen, B. R., The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin β-dependent nuclear localization signals. Mol. Cell. Biol. 1999, 19, 1210-1217.
44. Rothbard, J.B., Jessop, T.C., Wender, P.A., Adaptive translocation: The role of hydrogen binding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug Del. Rev. 2005, 57, 495-504.
45. Pooga, M., Soomets, U., Hällbrink, M., Valkna, A. et al., Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 1998, 16, 857-861.
46. Schwarze, S.R., Ho, A., Vocero-Akbani, A., Dowdy, S.F., In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999, 285, 1569-1572.
47. Drin, G., Rousselle, C., Scherrmann, J-M., Rees, A. R. et al., Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors. AAPS PharmSci. 2002, 4, 61-67.
48. Rousselle, C., Clair, P., Lefauconnier, J. M., Kaczorek, M. et al., New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000, 57, 679-686.
49. Rousselle, C., Smirnova, M., Clair, P., Lefauconnier, J.M. et al., Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: Saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 2001, 296, 124-131.
50. Deshayes, S., Konate, K., Aldrian, G., Crombez, L. et al., Structural polymorphism of non-covalent peptide-based delivery systems: Highway to cellular uptake. Biochim. Biophys. Acta 2010, 1798, 2304-2314.
51. Lindgren, M., Langel, Ü., Classes and prediction of cell-penetrating peptides. Methods Mol. Biol. 2011, 683, 3-19.
52. Pujals, S., Fernández-Carneado, J., López-Iglesias, C., Kogan, M.J. et al., Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta 2006, 1758, 264-279.
53. Fischer, R., Köhler, K., Fotin-Mleczek, M., Brock, R., A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 2004, 279, 12625-12635.
54. Suzuki, T., Futaki, S., Niwa, M., Tanaka, S. et al., Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 2002, 277, 2437-2443.
55. Jones, S., Lukanowska, M., Suhorutsenko, J., Oxenham, S. et al., Intracellular translocation and differential accumulation of cell penetrating peptides in bovine spermatozoa: Evaluation of efficient delivery vectors that do not compromise human sperm motility. Hum. Reprod. 2013, 28, 1874-1889.
56. Tyagi, M., Rusnati, M., Presta, M., Giacca, M., Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 2001, 276, 3254-3261.
57. Fotin-Mleczek, M., Welte, S., Mader, O., Duchardt, F. et al., Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J. Cell. Sci. 2005, 118, 3339-3351.
58. Kilk, K., Mahlapuu, R., Soomets, U., Langel, Ü., Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology 2009, 265, 87-95.
59. Crowley, P.B., Golovin, A., Cation-pi interactions in protein-protein interfaces. Proteins 2005, 59, 231-239.
60. Draeger, L.J., Mullen, G.P., Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J. Biol. Chem. 1994, 269, 1785-1793.
61. Giorello, L., Clerico, L., Pescarolo, M.P., Vikhanskaya, F. et al., Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 1998, 58, 3654-3659.
62. Pescarolo, M.P., Bagnasco, L., Malacarne, D., Valente, A. et al., A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. FASEB J. 2001, 15, 31-33.
63. Nieddu, E., Melchiori, A., Pescarolo, M.P., Bagnasco, L. et al., Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc. FASEB J. 2005, 19, 632-634.
64. Freeman, A.K., Ritt, D.A., Morrison, D.K., Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 2013, 49, 751-758.
65. Midgley, C.A., Desterro, J.M., Saville, M.K., Howard, S. et al., An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000, 19, 2312-2323.
66. Choi, J.M., Ahn, M.H., Chae, W.J., Jung, Y.G. et al., Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat. Med. 2006, 12, 574-579.
67. Choi, J.M., Ahn, M.H., Chae, W.J., Jung, Y.G. et al., Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc. Natl. Acad. Sci. U S A. 2008, 105, 19875-19880.
68. McCusker, C.T., Wang, Y., Shan, J., Kinyanjui, M.W. et al., Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J. Immunol. 2007, 179, 2556-25564.
69. Yoshida, T., Tomioka, I., Nagahara, T., Holyst, T. et al., Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem. Biophys. Res. Commun. 2004, 321, 961-966.
70. Iriyama, T., Kamei, Y., Kozuma, S., Takertani, Y., Bax-inhibiting peptide protects glutamate-induced cerebellar granule death by blocking Bax translocation. Neurosci. Lett. 2009, 451, 11-15.
71. Li, Y., Yokota, T., Gama, V., Yoshida, T. et al., Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ. 2007, 14, 2058-2067.
72. Qin, Q., Patil, K., Sharma, S. C., The role of Bax-inhibiting peptide in retinal ganglion cell apoptosis after optic nerve transection. Neurosci. Lett. 2004, 372, 17-21.
73. Wang, X., Han, W., Du, X., Zu, C. et al., Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury. Stroke 2010, 41, 2050-2055.
74. Han, B., Wang, Q., Cui, G., Shen, X. et al., Post-treatment of Bax-inhibiting peptide reduces neuronal death and behavioral deficits following global cerebral ischemia. Neurochem. Int. 2011, 58, 224-233.
75. Milano, G., Morel, S., Bonny, C., Samaja, M. et al., A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H1828-H1835.
76. Bonny, C., Oberson, A., Negri, S., Sauser, C. et al., Cell-permeable peptide inhibitors of JNK: Novel blockers of beta-cell death. Diabetes 2001, 50, 77-82.
77. Repici, M., Centeno, C., Tomasi, S., Forloni, G. et al., Time-course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation. Neuroscience 2007, 150, 40-49.
78. Reineke, K., Eminel, S., Dierck, F., Roessner, W. et al., The JNK inhibitor XG-102 protects against TNBS-induced colitis. PLoS One 2012, 7, e30985.
79. Touchard, E., Omri, S., Naud, M.C., Berdugo, M. et al., A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uvetis. Invest. Opthamol. Vis. Sci. 2010, 9, 4683-4693.
80. Suckfuell, M., Canis, M., Strieth, S., Scherer, H. et al., Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: A prospective randomized phaseI/II study. Acta Otolaryngol. 2007, 27, 938-942.
81. Siflinger-Birnboim, A., Johnson, A., Protein kinase C modulates pulmonary endothelial permeability: A paradigm for acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284, L435-L451.
82. Inagaki, K., Chen, L., Ikeno, F., Lee, F.H. et al., Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 2003, 2304-2307.
83. Kilpatrick, L.E., Sun, S., Li, H., Vary, T.C. et al., Regulation of TNF-induced oxygen radical production in human neutrophils: Role of delta-PKC. J. Leukoc. Biol. 2010, 87, 153-164.
84. Bates, E., Bode, C., Costa, M., Gibson, C.M. et al., Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008, 117, 886-896.
85. Fajloun, Z., Kharrat, R., Chen, L., Lecomte, C. et al., Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca(2+) release channel/ryanodine receptors. FEBS Lett. 2000, 469, 179-185.
86. Estève, E., Mabrouk, K., Dupuis, A., Smida-Rezgui, S. et al., Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane. J. Biol. Chem. 2005, 280, 12833-12839.
87. Poillot, C., Dridi, K., Bichraoui, H., Pêcher, J. et al., D-maurocalcine, a pharmacologically inert efficient cell-penetrating peptide analogue. J. Biol. Chem. 2010, 285, 34168-34180.
88. Löfgren, K., Wahlström, A., Lundberg, P., Langel, Ü. et al., Antiprion properties of prion protein-derived cell-penetrating peptides. FASEB J. 2008, 22, 2177-2184.
89. Higashijima, T., Uzu, S., Nakajima, T., Ross, E.M., Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). Biol. Chem. 1988, 263, 6491-6494.
90. Helle, K.B., The chromogranin A-derived peptides vasostatin-1 and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc. Res. 2010, 85, 9-16.
91. Angeletti, R.H., Aardal, S., Serck-Hanssen, G., Gee, P. et al., Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A. Acta Physiol. Scand. 1994, 152, 11-19.
92. Payne, C.K., Jones, S.A., Chen, C., Zhuang, X., Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 2007, 8, 389-401.
93. Shahnaz, G., Vetter, A., Barthelmes, J., Rahmat, D. et al., Thiolated chitosan nanoparticles for the nasal administration of leuprolide: Bioavailability and pharmacokinetic characterization. Int. J. Pharm. 2012, 428, 164-170.
94. Wang, Y., Li, Y., Shan, J., Fixman, E. et al., Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide. Clin. Exp. Allergy 2011, 4, 1622-1630.
95. Kamei, N., Nielsen, E.J., Khafagy, El-S., Takeda-Morishita, M., Noninvasive insulin delivery: The great potential of cell-penetrating peptides. Ther. Deliv. 2013, 4, 315-326.
96. Khafagy, El-S., Morishita, M., Isowa, K., Imai, J. et al., Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release 2009, 133, 103-108.
97. Khafagy, El-S., Morishita, M., Kamei, N., Eda, Y. et al., Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm. 2009, 381, 49-55.
98. Khafagy, El-S., Morishita, M., Takayama, K., The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int. J. Pharm. 2010, 388, 209-212.
99. Kanazawa, T., Taki, H., Tanaka, K., Takashima, Y. et al., Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm. Res. 2011, 28, 2130-2139.
100. Ezzat, K., Andaloussi, S.E., Zaghloul, E.M., Lehto, T. et al., PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res. 2011, 39, 5284-5298.
101. Andaloussi, S.E., Lehto, T., Mäger, I., Rosenthal-Aizman, K. et al., Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011, 39, 3972-3987.
102. Guichard, G., Benkirane, N., Zeder-Lutz, G., van Regenmortel, M.H. et al., Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc. Natl. Acad. Sci. USA 1994, 91, 9765-9769.
103. 10]MP. Regul. Pept. 2004, 121, 121-128.
104. Werle, M., Bernkop-Schnürch, A., Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006, 30, 351-367.
105. Wender, P.A., Galliher, W.C., Goun, E.A., Jones, L.R. et al., The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug. Deliv. Rev. 2008, 60, 452-472.
106. Simon, R.J., Kania, R.S., Zuckermann, R.N., Huebner, V.D. et al., Peptoids: a modular approach to drug discovery. Proc. Natl. Acad. Sci. USA 1992, 89, 9367-9371.
107. Clark, R.J., Fischer, H., Dempster, L., Daly, N.L. et al., Engineering stable peptide toxins by means of backbone cyclization: Stabilization of the alpha-conotoxin MII. Proc. Natl. Acad. Sci. USA 2005, 102, 13767-13772.
108. Trabi, M., Craik, D.J., Circular proteins - no end in sight. Trends Biochem. Sci. 2002, 27, 132-138.
109. Scholl, M., Trnka, T.M., Morgan, J.P., Grubbs, R.H., Increased ring closing metathesis activity of ruthenium-based olefin metathesis catalysts coordinated with imidazolin-2-ylidene ligands. Tetrahedron Lett. 1999, 40, 2247-2250.
110. Sidhu, S.S., Lowman, H. B., Cunningham, B.J., A. Wells, J.A., Phage display for selection of novel binding peptides. Method. Enzymol. 2000, 328, 333-363.
111. Aina, O.H., Liu, R., Sutcliffe, J.L., Marik, J. et al., From combinatorial chemistry to cancer-targeting peptides. Mol. Pharm. 2007, 4, 631-651.
112. Rivinoja, A., Laakkonen, P., Identification of homing peptides using the in vivo phage display technology. Methods Mol. Biol. 2011, 683, 401-415.
113. Eriste, E., Kurrikoff, K., Suhorutsenko, J., Oskolkov, N. et al., Peptide-based glioma-targeted drug delivery vector gHope2. Bioconjug. Chem. 2013, 24, 305-313.
114. Wan, X.M., Chen, Y.P., Xu, W.R., Yang, W.J. et al., Identification of nose-to-brain homing peptide through phage display. Peptides 2009, 30, 343-350.
115. Reichert, J., Pechon, P., Tartar, A., Dunn, M.K., Development trends for peptide therapeutics. Peptide Therapeutics Foundation 2010 Report.
116. Kelemen, B.R., Hsiao, K., Goueli, S.A., Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J. Biol. Chem. 2002, 277, 8741-8748.
117. Kalinichenko, V.V., Major, M.L., Wang, X., Petrovic, V. et al., Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004, 18, 830-850.
118. Snyder, E.L., Meade, B.R., Saenz, C.C., Dowdy, S.F. et al., Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2004, 2, e36.
119. Arnt, C.R., Chiorean, M.V., Heldebrant, M.P., Gores, G.J. et al., Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem 2002, 277, 44236-44423.
120. Plescia, J., Salz, W., Xia, F., Pennati, M. et al., Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 457-468.
121. Hirose, M., Takatori, M., Kuroda, Y., Abe, M. et al., Effect of synthetic cell-penetrating peptides on TrkA activity in PC12 cells. J. Pharmacol. Sci. 2008, 106, 107-113.
122. Lavaur, J., Bernard, F., Trifilieff, P., Pascoli, V. et al., A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J. Neurosci. 2007, 27, 14448-1458.
123. Makino, E., Sakaguchi, M., Iwatsuki, K., Huh, N-H., Introduction of an N-terminal peptide of S100C/A11 into human cells induces apoptotic cell death. J. Mol. Med. (Berl). 2004, 82, 612-620.
124. Jones, S., Farquhar, M., Martin, A., Howl, J., Intracellular translocation of the decapeptide carboxyl terminal of Gi3a induces the dual phosphorylation of p42/p44 MAP kinases. Biochim. Biophys. Acta 2005, 1745, 207-214.
125. Howl, J., Jones, S., Farquhar, M., Intracellular delivery of bioactive peptides to RBL-2H3 cells induces β-hexoseaminidase secretion and phospholipase D activation. ChemBioChem 2003, 1312-1316.
126. Baker, R.D., Howl, J., Nicholl, I.D., A sychnological cell penetrating peptide mimic of p21(WAF1/CIP1) is pro-apoptogenic. Peptides 2007, 28, 731-470.
127. Low, W., Mortlock, A., Petrovska, L., Dottorini, T. et al., Functional cell permeable motifs within medically relevant proteins. J. Biotechnol. 2007, 129, 555-564.
128. Östlund, P., Kilk, K., Lindgren, M., Hällbrink, M. et al., Cell-penetrating mimics of agonist-activated G-protein coupled receptors. Int. J. Pept. Res. Ther. 2005, 11, 237-247.